Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9701)	4/23/1999 5:03:00 AM
From: opalapril	Read Replies (1) \| Respond to of 17367

Great find, albeit depressing to read Xoma's possible future in the history books. <EOM>

To: Cacaito who wrote (9701)	4/25/1999 1:41:00 AM
From: aknahow	Respond to of 17367

Cacaito, I went to Raging Bull and found a board hosted by Emmanuel Tzavlak, who apparently is with Novarits. I asked him a question on the XOMA HE process, and while he did not respond to this said he owns some XOMA and he likes their science. Read his exact words at: ragingbull.com Post 190 was mine and 194 contains his reply to it and post by others.

To: Cacaito who wrote (9701)	4/25/1999 2:17:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacaito, here is the background of Tzavlak. Manny Tzavlakis has held various strategy positions within the healthcare industry. Currently, he is employed as a senior analyst at Novartis Pharmaceuticals where he covers a myriad of pharmaceutical/biotechnology topics. He has also worked in Strategic Planning at CIGNA HealthCare and at a CI consulting firm where he had BMS, Pfizer and Amgen as clients

To: Cacaito who wrote (9701)	4/28/1999 8:29:00 AM
From: Robert K.	Respond to of 17367

Further standard k disclaimer. I am long the stock (for now). Have traded smallish amounts recently. ( voluntary disclosure) Does not mean I will disclose in the future.(I probably wont) Standard K.

To: Cacaito who wrote (9701)	4/29/1999 1:24:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Description in detail of a different clinical trial for meningococcal sepsis. NOTE the reference to 30% mortality for patients with glasgow of 8 or above! Does not mean it is not lower in the U.K. but supports what you have said many times. "The inclusion criteria for the patients should be SAPF with a Glasgow meningoccocal septicaemia prognostic score of 8 or >8 which predicts a mortality of about 30 % or more." kfunigraz.ac.at One more day at the BARGA meeting in Italy.